STK11 and non-small cell lung carcinoma: Arbour et al. showed that among 330 patients with late stage KRAS-mutant NSCLC, the most frequent comutations were found in TP53 (42%), STK11 (29%) and KEAP1/NFE2L2 (27%) [101].